Brief: CanSino's Bivalent Coronavirus mRNA Vaccine Receives Approval For Clinical Trial
16/04/2023 08:46
April 16 (Reuters) - CanSino Biologics Inc 688185.SS :
* SAYS ITS BIVALENT CORONAVIRUS MRNA VACCINE RECEIVES
APPROVAL FOR
CLINICAL TRIAL
Source text
Further company coverage: 688185.SS
(Reporting by Hong Kong newsroom)
((twinnie.siu@tr.com; 852-3462 7715;))
Recent news on Cansino Biologics
See all newsBrief: CanSino Biologics Says China's NMPA Granted Priority Review Status To NDA For TD5CP Adolescent, Adult
Brief: CanSino Biologics Reports Widened Net Loss For Q1
Brief: CanSino Biologics Says 2025 Net Profit At 27.9 Million Yuan
Brief: CanSino Biologics Prelim 2025 Net Profit At 27.9 Million Yuan
Brief: CanSino Biologics Expects To Have Returned to Net Profit In 2025